108 related articles for article (PubMed ID: 33073195)
1. The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?
Ghanem M; Archer G; Crestani B; Mailleux AA
Pharmacol Ther; 2024 Jul; 259():108669. PubMed ID: 38795981
[TBL] [Abstract][Full Text] [Related]
2. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).
Wu X; Ge H; Lemon B; Vonderfecht S; Baribault H; Weiszmann J; Gupte J; Gardner J; Lindberg R; Wang Z; Li Y
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14158-63. PubMed ID: 20660733
[TBL] [Abstract][Full Text] [Related]
3. Enhanced bioactivity and stability of a long-acting FGF21: A novel variant for the treatment of NASH.
Ji Y; Lu Q; Duan Y; Chen X; Zhang Y; Yao W; Yin J; Gao X
Biochimie; 2024 May; 225():26-39. PubMed ID: 38740172
[TBL] [Abstract][Full Text] [Related]
4. Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans.
Lauritzen ES; Svart MV; Voss T; Møller N; Bjerre M
Endocr Res; 2021 Feb; 46(1):20-27. PubMed ID: 33074729
[TBL] [Abstract][Full Text] [Related]
5. FGF21 Enhances Therapeutic Efficacy and Reduces Side Effects of Dexamethasone in Treatment of Rheumatoid Arthritis.
Sun X; Xie YZ; Jiang YY; Wang GY; Wang YJ; Mei Y; Gao RH; Li YH; Xiao W; Wang WF; Li DS
Inflammation; 2021 Feb; 44(1):249-260. PubMed ID: 33098521
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women.
Ramanjaneya M; Bensila M; Bettahi I; Jerobin J; Samra TA; Aye MM; Alkasem M; Siveen KS; Sathyapalan T; Skarulis M; Atkin SL; Abou-Samra AB
Front Endocrinol (Lausanne); 2020; 11():568500. PubMed ID: 33101202
[No Abstract] [Full Text] [Related]
7. FXR in the dorsal vagal complex is sufficient and necessary for upper small intestinal microbiome-mediated changes of TCDCA to alter insulin action in rats.
Zhang SY; Li RJW; Lim YM; Batchuluun B; Liu H; Waise TMZ; Lam TKT
Gut; 2021 Sep; 70(9):1675-1683. PubMed ID: 33087489
[TBL] [Abstract][Full Text] [Related]
8. PPARα Agonist Oral Therapy in Diabetic Retinopathy.
Tomita Y; Lee D; Tsubota K; Kurihara T
Biomedicines; 2020 Oct; 8(10):. PubMed ID: 33086679
[TBL] [Abstract][Full Text] [Related]
9. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success.
Drenth JPH; Schattenberg JM
Expert Opin Investig Drugs; 2020 Dec; 29(12):1365-1375. PubMed ID: 33074035
[TBL] [Abstract][Full Text] [Related]
10. Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability.
Niu J; Zhao J; Wu J; Qiao G; Gu J; Zhou C; Li Q; Ying L; Wang D; Lin H; Li X; Mohammadi M; Huang Z
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):29025-29034. PubMed ID: 33144503
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Baruch A; Wong C; Chinn LW; Vaze A; Sonoda J; Gelzleichter T; Chen S; Lewin-Koh N; Morrow L; Dheerendra S; Boismenu R; Gutierrez J; Wakshull E; Wilson ME; Arora PS
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28992-29000. PubMed ID: 33139537
[TBL] [Abstract][Full Text] [Related]
12. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
[TBL] [Abstract][Full Text] [Related]
13. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
Henriksson E; Andersen B
Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
[TBL] [Abstract][Full Text] [Related]
14. Branched Multimeric Peptides as Affinity Reagents for the Detection of α-Klotho Protein.
Ye X; Zhang P; Wang JCK; Smith CL; Sousa S; Loas A; Eaton DL; Preciado López M; Pentelute BL
Angew Chem Int Ed Engl; 2023 May; 62(19):e202300289. PubMed ID: 36894520
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
16. Glucagon receptor signaling regulates weight loss via central KLB receptor complexes.
Nason SR; Antipenko J; Presedo N; Cunningham SE; Pierre TH; Kim T; Paul JR; Holleman C; Young ME; Gamble KL; Finan B; DiMarchi R; Hunter CS; Kharitonenkov A; Habegger KM
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33411693
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21.
Pan J; Parlee SD; Brunel FM; Li P; Lu W; Perez-Tilve D; Liu F; Finan B; Kharitonenkov A; DiMarchi RD
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):978-986. PubMed ID: 33073195
[TBL] [Abstract][Full Text] [Related]
18. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.
Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD
Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271
[TBL] [Abstract][Full Text] [Related]
19. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
